Aoxing Pharma revenue falls in FY2010
The reduction of revenue occurred because Aoxing consolidated its manufacturing facilities in the summer of 2009, requiring re-certification or the facilities by the Chinese government. Loss from operations
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.